Coave Therapeutics at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Coave Therapeutics brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV vectors carrying chemical ligands that steer them to chosen tissues. Topics include suprachoroidal delivery that reaches the back of the eye with therapeutic anti-VEGF levels in primates and a programmable platform for on-demand targeting.

OrganizationESGCT 2026 Attendance
Coave Therapeutics
Paris, France
coavetx.com
Biotech
Clinical-stage company developing gene therapies for rare eye and central nervous system diseases, using ligand-conjugated AAV vectors that target specific tissues.
Poster
Thu Oct 29
2:00pm–4:00pm
A novel suprachoroidal AAV vector engineered with ALIGATERTM achieves unprecedented posterior segment targeting and therapeutic anti-VEGF levels in NHP
CNS & sensory
Poster
Thu Oct 29
2:00pm–4:00pm
OneAAV™: a programmable ligand-conjugated AAV Platform for on-demand tissue targeting across therapeutic applications
AAVs / non integrative vectors

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Coave Therapeutics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction